Results from the ATHENA trial, reported in the 12th February issue of the New England Journal of Medicine, suggest that the (as yet unlicensed) antiarrhythmic drug dronedarone can reduce the incidence of cardiovascular-related hospitalisation or death in patients with atrial fibrillation. The study was performed at more than 550 centres in 37 countries.
The ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation have described dronedarone as a derivative of amiodarone (a well established and recommended treatment for atrial fibrillation) under development as an ion-channel blocking drug.
Speaking on behalf of the European Society of Cardiology, Professor Christophe Leclercq from the CHU in Rennes, France, said: “The ATHENA trial shows that dronedarone, a new antiarryhtmic drug similar to amiodarone but with different effects on individual ion channels, reduced the risk of death or hospitalisation for cardiovascular reasons by 36% when compared with placebo. This was in patients without severe heart failure (NYHA class IV) but with paroxysmal or persistent atrial fibrillation or flutter with additional risk factor for death.
“The study found no difference in overall mortality between the two groups but cardiovascular death was significantly reduced with dronedarone by 29%. There was no difference in thyroid-related effects between the two groups. The EURIDIS and ADONIS trials have already shown that dronedarone significantly reduced the recurrence of arrythmias in patients with paroxysmal or persistent atrial fibrillation.
“Dronedarone may thus play a role in the management of atrial arrhythmias in patients with paroxysmal or persistent atrial tachycardias without severe heart failure.”
REFERENCES:1. Hohnloser SH, Crijns HJGM, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med 2009; 360: 668-678.
Anne Strauss | alfa
Further reports about: > ACC/AHA/ESC > Experimental antiarrhythmic drug > Placebo > antiarrhythmic drug > atrial fibrillation > cardiovascular risk factor > cardiovascular-related hospitalisation > death rate > derivative of amiodarone > dronedarone > fewer deaths > heart failure > ion-channel blocking drug > paroxysmal > persistent atrial tachycardias > risk factor
Multi-year study finds 'hotspots' of ammonia over world's major agricultural areas
17.03.2017 | University of Maryland
Diabetes Drug May Improve Bone Fat-induced Defects of Fracture Healing
17.03.2017 | Deutsches Institut für Ernährungsforschung Potsdam-Rehbrücke
Astronomers from Bonn and Tautenburg in Thuringia (Germany) used the 100-m radio telescope at Effelsberg to observe several galaxy clusters. At the edges of these large accumulations of dark matter, stellar systems (galaxies), hot gas, and charged particles, they found magnetic fields that are exceptionally ordered over distances of many million light years. This makes them the most extended magnetic fields in the universe known so far.
The results will be published on March 22 in the journal „Astronomy & Astrophysics“.
Galaxy clusters are the largest gravitationally bound structures in the universe. With a typical extent of about 10 million light years, i.e. 100 times the...
Researchers at the Goethe University Frankfurt, together with partners from the University of Tübingen in Germany and Queen Mary University as well as Francis Crick Institute from London (UK) have developed a novel technology to decipher the secret ubiquitin code.
Ubiquitin is a small protein that can be linked to other cellular proteins, thereby controlling and modulating their functions. The attachment occurs in many...
In the eternal search for next generation high-efficiency solar cells and LEDs, scientists at Los Alamos National Laboratory and their partners are creating...
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are less stable. Now researchers at the Technical University of Munich (TUM) have, for the first time ever, produced a composite material combining silicon nanosheets and a polymer that is both UV-resistant and easy to process. This brings the scientists a significant step closer to industrial applications like flexible displays and photosensors.
Silicon nanosheets are thin, two-dimensional layers with exceptional optoelectronic properties very similar to those of graphene. Albeit, the nanosheets are...
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to simulate these confined natural conditions in artificial vesicles for the first time. As reported in the academic journal Small, the results are offering better insight into the development of nanoreactors and artificial organelles.
Enzymes behave differently in a test tube compared with the molecular scrum of a living cell. Chemists from the University of Basel have now been able to...
20.03.2017 | Event News
14.03.2017 | Event News
07.03.2017 | Event News
24.03.2017 | Materials Sciences
24.03.2017 | Physics and Astronomy
24.03.2017 | Physics and Astronomy